Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Baird Medical Highlights Johns Hopkins Cost-Utility Analysis Supporting TNA For Thyroid Nodules At ATA Annual Meeting

Author: Benzinga Newsdesk | October 14, 2025 08:38am

Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("BAIRD MEDICAL" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, highlighted the significant findings of a cost-utility analysis conducted by researchers at Johns Hopkins University. The study abstract, presented at the recent American Thyroid Association (ATA) Annual Meeting, concludes that management strategies incorporating transcutaneous thyroid nodule ablation (TNA) can lead to lower healthcare costs and improved patient quality of life.

Posted In: BDMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist